Herpes Simplex Virus Establishment, Maintenance, and Reactivation: In Vitro Modeling of Latency

Nikki M. Thellman and Steven J. Triezenberg *
Van Andel Research Institute, Grand Rapids, MI 49503, USA; nikki.thellman@vai.org
* Correspondence: steve.triezenberg@vai.edu; Tel.: +01-616-234-5704
Received: 25 May 2017; Accepted: 6 June 2017; Published: 23 June 2017

Abstract: All herpes viruses establish lifelong infections (latency) in their host, and herpes simplex viruses (HSV) are highly prevalent worldwide. Recurrence of HSV infections contributes to significant disease burden in people and on rare occasion can be fatal. Cell culture models that recapitulate latent infection provide valuable insight on the host processes regulating viral establishment and maintenance of latency. More robust and rapid than infections in live animal studies, advancements in neuronal culture techniques have made the systematic analysis of viral reactivation mechanisms feasible. Only recently have human neuronal cell lines been available, but models in the natural host cell are a critical addition to the currently available models.

Keywords: latent infection; lytic infection; HSV-1; HSV-2; neuron; quiescent infection; cell culture

1. Introduction: Current Clinical Outlook

The significant global prevalence of herpes simplex viruses (HSV) is largely due to the fact that a defining characteristic of the herpesviruses is lifelong infection. Recent models estimate that in 2012, the global prevalence for HSV type-1 (HSV-1) in people aged 0–49 years was 3.7 billion (67%) [1], and the prevalence for HSV-2 in people aged 15–49 years was over 400 million (11.3%) [2]. Herpesviruses employ two contrasting infection strategies to ensure both transmission of virus and long-term infection. Replication and viral shedding is referred to as lytic or productive infection, whereas latent infection refers to a quiescent state where viral genomic material persists in cells of the host, poised for reactivation.

HSV-2 is most commonly spread by sexual contact [3], whereas HSV-1 is frequently acquired through oral secretions as a mucosal infection during early childhood [4], although the epidemiology is changing such that many countries are seeing increasing sexually transmitted infections of HSV-1 [5]. Most often, the reactivation of latent HSV leads to recurring ulcerative blisters at the mucosal surfaces near the primary site of infection (orolabial or genital herpes) [6], but other painful lesions can occur as well [7]. Reactivation resulting in ocular lesions, such as herpetic epithelial or stromal keratitis, can lead to blindness [8,9]. In rare cases, HSVs can cause encephalitis [10], most notably in neonates born to mothers shedding either genital HSV-1 or HSV-2 [11,12] or in adults due to the reactivation of HSV-1 [13–15].

The lytic infection cycle of HSV has been well studied, and as such, is the primary target of most antiviral therapeutic drugs [16]. Acyclovir (acycloguanosine) was first designed as an antiherpetic drug in 1977 and remains the primary therapeutic approach today [17]. Acyclovir and its derivatives inhibit viral replication and reduce the duration and severity of clinical signs. Unfortunately, these therapies do not prevent recurrence arising from the reactivation of the latent virus [18]. In addition, viral strains resistant to acyclovir occur in immunocompromised patients [19–22] and in patients with herpetic keratitis treated with prophylactic acyclovir [23].

Therefore, new treatments that prevent the painful, sometimes life-threatening recurrence of HSV infections could benefit a significant portion of the human population. Unfortunately, the molecular
mechanisms underlying viral reactivation are poorly understood, arising in part from a lack of robust experimental models in which the critical molecules involved in HSV reactivation can be studied. For many years, in vivo models using small animals (especially mice, rabbits, and guinea pigs) have been used to characterize latency in an anatomically and immunologically relevant context. Animal models are expensive and time-consuming. In vivo infections take over a month to establish latency. Moreover, latent virus is typically found in less than 20% of neurons [24,25], and only a small fraction of those latently-infected neurons will reactivate following experimental induction. As a result, molecular studies of viral reactivation mechanisms using in vivo models have been limited [26].

With recent advances in neuronal culturing techniques, however, in vitro cell culture models have emerged as powerful tools to study the molecular and genetic mechanisms of HSV latency and reactivation. Cell culture models offer several research advantages, including consistency, reproducibility, and cost-effectiveness. The expression or activity of viral and cellular proteins can be more readily modulated in cell culture by genetic approaches (including targeted gene editing), RNA interference, or pharmacological agents. In addition, confounding contributions from inflammatory or support cells are removed, providing an opportunity to study viral mechanisms at the single cell level. The purpose of this review is to examine the different HSV latency cell-culture models currently available, highlighting the specific contributions and advantages of each model.

2. HSV Life Cycle: Recapitulating the Latent Infection

HSVs are highly complex, with genomes that encode essential enzymes for gene regulation, DNA replication, processing, and packaging. In a lytic infection of the epithelium, virion protein 16 (VP16) is delivered as a tegument protein and drives viral gene expression by complexing with host cell proteins Oct-1 and HCF1. This VP16-induced complex recruits general transcription machinery to viral immediate early (IE) gene promoters, triggering lytic gene expression [27–31]. Lytic gene expression is highly ordered, with the IE gene products setting off a cascade of viral early and late gene expression, allowing DNA synthesis and nucleocapsid assembly to take place in the nucleus [32,33]. Virion assembly and maturation continues in the cytoplasm.

In contrast, latent infections are established under conditions in which the mechanisms driving the efficient, organized lytic life cycle are not adequately supported. Virus particles released from lytically-infected epithelial tissue enter the innervating sensory neuron axons. Capsids carrying viral genomes are released into the cytoplasm and traverse to the neuronal soma in ganglia driven by microtubule-based molecular motors; cytoplasmic dynein provides the motor force for retrograde movements towards the soma [34]. Capsids deliver viral genomes to neuronal nuclei where a non-productive infection (latency) occurs. One current hypothesis considers the architecture of the innervating neuron to be a key component in the process [35]. The extensive trafficking of capsids through long axons results in the inefficient transport of tegument proteins (such as VP16) to the nucleus, and subsequently in insufficient transcriptional activation of IE gene expression [35,36]. Without the robust expression of immediate early proteins, histone deposition across viral genomes is more prominent [37,38], favoring genome repression by epigenetic regulation.

Operationally, latency is described as “the persistence of a viral genome within tissue where, at any given time, there is a population of cells that lack detectable infectious virus, viral proteins, or viral lytic transcripts that are dormant but have the capability of being reactivated” [26]. During latency, the viral genome is stably maintained in the neuronal nucleus, where it persists as an episome [39] carrying marks of heterochromatin at lytic genes [40–42]. Viral genomes are therefore transcriptionally repressed during latency with the exception of expression of a non-coding RNA known as the latency-associated transcript (LAT). LAT is spliced to yield a stable 2.0 kb intron that accumulates in neurons and is believed to be important in maintaining HSV latency, although the mechanisms of LAT action remain under investigation [43,44]. Physiological triggers in the host result in cellular stresses that re-animate the latent virus in neurons; genomes are actively transcribed, replicate, and produce viral particles de novo that are transported back to the mucosal surface to cause a lesion (reactivation). The terminology
used to describe HSV latency has been refined over the years, as recently reviewed by Sawtell and Thompson. They proposed a partitioning of the process of reactivation from latency into a series of events including pre-initiation (comprising reversible changes in signaling or viral chromatin), exit from latency (detectable expression of viral proteins), and reactivation (presence of infectious virus from cells where none had been present), and argue that consistent and common use of the latency lexicon will help to illuminate aspects of these mechanisms that might emerge from various experimental models [45].

The longstanding challenge in recapitulating HSV latency in cell culture involves simplifying a complex process with multiple steps (establishment, maintenance, and reactivation) [46] and multiple anatomical compartments (mucosa and ganglia). Consequently, most of the two-dimensional cell culture systems are permissive to lytic infection and require experimental conditions that favor non-productive infection, such as treatment with acyclovir, using low multiplicities of infection, or using replication-defective mutants. These experimental conditions do contribute to different limitations of different cell culture models. However, the analysis of molecular and genetic events specific to viral latency or reactivation is still more accessible in a cell culture compared to in vivo studies.

Defining the specific site of HSV latency, one aspect necessary in building a relevant model, has been historically challenging. The current consensus is that HSV is most frequently found in sensory neurons that innervate the primary site of infection [47]. For example, latent HSV-1 can be found in the trigeminal ganglia (TG) that innervate the lips, gingiva, and eyes, and latent HSV-2 can be found in the dorsal root ganglia (DRG) that innervate the skin and muscle of the back as well as the mucosa of the genitalia [48]. This consensus, however, is most likely an oversimplification; other ganglia, including sympathetic neurons from vestibular, geniculate, spiral, and sacral ganglia have been documented as sites of HSV latency [49–52]. Interestingly, an argument for non-neuronal sites of latency re-emerged in 2015, when evidence of HSV latency in corneas of patients with herpetic keratitis was reported [53]; to date, no robust model for ocular latency has yet been described. For now, many in the field agree that neurons are the preferred cell type in which to recapitulate latent infection in cell culture.

3. Latency Cell Culture Models

Unfortunately, reliable, ethical, and reproducible sources of neurons for cell culture investigation of HSV latency are hard to come by. For ethical reasons, human neuronal tissue is not readily available for primary culture. Here we examine the different HSV latency cell culture models that are currently available, which we segregate into three categories (i) non-neuronal; (ii) non-human neuronal; and (iii) human neuronal cell lines. Each model provides unique opportunities to study different aspects of HSV latency and reactivation (Table 1). In our opinion, when the findings from these models are taken into consideration collectively, progress in addressing critical gaps in understanding the molecular and genetic components of latency and reactivation can be made.

| Model class        | Example                          | Advantages                                      | Disadvantages                                      |
|--------------------|----------------------------------|-------------------------------------------------|---------------------------------------------------|
| Non-neuronal       | Normal diploid human fibroblasts | Readily available, rapid proliferation, reproducible source | Not natural cell types for HSV latency             |
|                    | Rat pheochromocytoma (PC12)     | "                                               | Host proteins important for virus infection may differ |
| Non-human neuronal | Rat prenatal sympathetic neurons | Suitable cell type for HSV latency              | Rodent, not human; Molecular, physiological differences |
|                    | Rat neonatal or adult DRG, SCG neurons | "                                               | Challenging to procure and culture                 |
|                    |                                  |                                                 | No proliferation/long-term storage                 |
3.1. Non-neuronal Culture Models

Quiescent states that resemble HSV latency can be established in certain non-neuronal cell lines. Initially, HSV-1 quiescent infections were established in fibroblasts using a combination of elevated temperatures and replication inhibitors [54–56]. Quiescence with HSV-2 was established using elevated temperatures and a very low multiplicity of infection [57]. In another example, a non-replicating, non-toxic infection state was established in normal human diploid fibroblasts upon infection with HSV-1 mutants impaired for IE gene expression [58]. More recently, one report demonstrated quiescent wild-type HSV-1 infection of primary (serum starved) human diploid fibroblasts without the use of chemical replication inhibitors, by inducing heat shock (HS) proteins through elevated pre-incubation temperatures [59]. Using this fibroblast model and wildtype virus, entry into a quiescent state was characterized by the expression of some IE proteins (ICP4, ICP22), but a failure to process ICP22 and inefficient production of ICP0, all resulting in low-level viral replication [59]. These non-neuronal models have the advantage that the cells readily proliferate, generating ample material for experiments. Therefore, the pathways necessary for the establishment of latency can be studied in a human cell type in a rapid and robust manner.

Another interesting model uses rat pheochromocytoma (PC12) cells which were derived from a type of endocrine tumor from the adrenal gland that has neural crest origins [60]. Although not technically considered neurons, they can be differentiated into “neuron-like” cells when treated with nerve growth factor (NGF) or dexamethasone. Neuronally differentiated PC12 (ND-PC12) cells have been used to study HSV-1 quiescent infection from which the virus can reactivate following cellular stressors such as heat shock (43 °C for 3 h) or treatment with forskolin [61–63]. One specific study used a series of viral mutants with various deletions in the VP16 transactivation domain to evaluate the importance of specific sub-regions (VP16N and VP16C) for IE gene expression and stress-induced reactivation [64]. This approach is not feasible in vivo due to the poor replication of mutant strains. In ND-PC12 cells, however, equivalent viral genome copy numbers of mutant and wild-type viruses established quiescence. After reactivation was induced, neurons demonstrated unique regulation of IE gene activation and the VP16 transactivation domain was found to be critical for reactivation [64].

Both of these systems are simple and efficient; these cell lines proliferate readily and provide opportunities to use biochemical or molecular assays to study the quiescent infection of wild-type HSV-1. In addition, there is no need for the dissection of animal tissue for primary culture, thus saving time and reducing animal use. Diploid fibroblast models allow quiescent infection to be studied specifically in human cells, which provides a natural host-cell context. Unfortunately, fibroblasts are not the cell type in which latency and reactivation naturally occur [65]. Whereas ND-PC12 cells do offer a “neuronal-like” state, they are not human and only appear morphologically similar to neurons.

### Table 1. Cont.

| Model class                      | Example                           | Advantages                                               | Disadvantages                                      |
|----------------------------------|-----------------------------------|----------------------------------------------------------|----------------------------------------------------|
| Human neuronal                   | Neuroblastoma (SH-SY5Y), differentiated | Readily available, rapid proliferation, reproducible source | Neural crest but not neuronal origin: HSV latency not established |
| Teratocarcinoma (NT2), differentiated | “                                 | Not neuronal origin                                       |                                                    |
| Induced pluripotent stem cells   | “                                 | Challenging to culture, heterogeneous, HSV latency not established |                                                    |
| iPSCs                            | Commercially available, less heterogeneous than iPSC-derived cultures | Expensive, HSV latency not yet established |                                                    |
| Immortalized ganglion cell lines (HD10.6) | Rapid proliferation, reproducible source, suitable cell type for HSV latency | Multiple neurotrophin receptors; inefficient reactivation of HSV | |
Host cell proteins that are critical in HSV gene regulation differ both in expression levels and cellular localization in neurons compared to non-neuronal cell types. For example, the POU (Pit-1/Oct/Unc-86) domain transcription factor Oct-1 is robustly expressed in epithelial cells and is, as previously mentioned, a critical gene regulatory protein that complexes with VP16 and HCF1 [32]. In sensory neurons, however, other POU domain proteins such as Brn-2 and Brn-3A are more robustly expressed [66] and these may bind to IE promoters with a higher affinity than Oct-1 [29,67]. In addition, HCF1 is an important cell cycle regulatory protein that in most cells localizes to the nucleus [68,69]. In sensory neurons, however, HCF1 localizes in the cytoplasm [70]. This may play a role in favoring a non-productive infection in neurons if HCF1 differentially binds VP16 in distal axons, impeding its trafficking to the nucleus [41]. Lastly, mouse fibroblasts lacking Oct-1 are impaired for HSV infection at low multiplicity but not high multiplicity, with deficits in both IE gene expression and DNA replication [71]. This supports the notion that mechanisms of HSV latency and reactivation should also be investigated in neurons, which presumably express the host cellular machinery of the natural site for viral latency.

3.2. Non-Human Neuronal Culture Models

The first latent infection of cultured neurons was reported by Wilcox and Johnson in the late 1980s, in which primary sympathetic neuronal tissue from prenatal rats was infected with either HSV-1 or HSV-2 in the presence of acyclovir [72,73]. Cultures that were initially shown to be quiescent (no viral antigens detected with immunohistochemistry) could be reactivated by NGF deprivation [73]. Some years later, the use of cultured rodent neurons re-emerged as a way to model latency in vitro. One group dissociated neonatal rat DRG and infected with lytic-gene reporter viruses developed on the backbone of a replication-defective mutant virus to better characterize primary infection and establishment of latency in neurons [74]. Specifically, this group demonstrated that from three days post-infection, the lytic phase expression was shut down whereas the expression from the LAT promoter was highly variable, suggesting that certain neuronal subtypes may be more permissive than others for LAT expression during latency [74]. The use of replication-defective virus strains limits the ability to study complete reactivation in this model, since productive infection is the final hallmark of reactivation. Still, early parts of the process of reactivation can be studied in this model; for example, NGF deprivation or treatment with trichostatin A (a histone deacetylase inhibitor) resulted in the activation of lytic promoters [74], giving an early indication for the role of epigenetic regulation in the maintenance of HSV latency.

Mohr and Wilson established latency using wild-type HSV-1 in a manner similar to the Wilcox model, in which superior cervical ganglia from prenatal rats were infected in the presence of acyclovir [75]. After treatment with an anti-mitotic agent, dissociated sympathetic neurons provided a near-homogenous population of cells that express one of the neurotrophin tyrosine receptor kinases, TrkA, which is expressed in some nociceptive sensory neurons. In this model, viral genomes were maintained at an average copy number of 25 per neuron, with LAT expression persisting in neuronal nuclei; lytic mRNAs and proteins and infectious virus were undetectable. Reactivation was induced by disruption of the NGF-TrkA pathway, either by direct NGF deprivation or by modulation of downstream signaling through PI3 kinase, AKT, and mTOR using shRNA knockdown or pharmacological inhibition [76,77], indicating that these signaling molecules were critical for maintaining the viral genome in a latent state [76]. Moreover, by growing primary neurons in compartmentalized culture systems such that media for axons are separated from media for neuronal cell bodies, spatial-specific parameters of HSV latency in neurons can be investigated [35]: latent HSV genomes in dissociated rodent ganglia soma responded to localized changes in mTOR signaling in axons [77]. The transition from latent to lytic transcription (reactivation) was carefully profiled using this model and revealed two distinct waves of viral mRNA accumulation during the exit from latency [41].
These models have enabled the molecular analysis of mechanisms necessary in maintaining HSV-1 in a latent state in a neuron, much like the cell type in the natural host. However, the permissiveness of rodent ganglia tissue to HSV lytic infection in culture means that either acyclovir treatment or replication-defective mutants are required to establish a non-productive infection. One potential critique of using acyclovir is that the guanine analogue may lead to stalled viral replication forks [78] and thus establish an aberrant latent state in which viral DNA is incompetent for subsequent replication and reactivation.

Some hypothesize that adult-rodent ganglia are less permissive to lytic infection than immature (embryonic or neonatal) ganglia and therefore do not require acyclovir. Margolis and Bertke infected dissociated adult mouse TG with HSV-1 and HSV-2 and demonstrated the establishment of latency without the use of acyclovir [79]. This adult sensory-neuron model also revealed a virus type (HSV-1 versus HSV-2) preference for establishing latency in specific nociceptive-neuron subtypes (A5+ versus KH10+, respectively) that may be driven by the differences in virus-type LAT expression [80,81]. Specifically, HSV-2 LAT contains a cis-acting regulatory element near the transcription start site that promotes productive infection in A5+ neurons and a second element in exon 1 that inhibits productive infection in KH10+ neurons, whereas HSV-1 does not contain such regulatory sequences and subsequently productive infection is not promoted in A5+ neurons [80].

A recent report illustrates the value of using non-human neurons to probe the roles of specific molecular pathways in regulating latency and reactivation. In this case, latent infection was established in dissociated sympathetic (superior cervical ganglia) and sensory neurons (TG) from adult mice using acyclovir [82]. The use of a number of pharmacological inhibitors revealed that during stress-induced reactivation, the c-Jun N-terminal kinase (JNK) activated the DLK/JIP-3 proteins which mediate the methylation and phosphorylation of specific amino acids of histone H3 in nucleosomes of latent viral genomes, and subsequently triggered early viral gene expression by initiating changes in chromatin structure that favor gene activation [82]. Compared to in vivo infections, latency can rapidly be established in dissociated primary ganglia (one week compared to one month) and results in an increased number of latently infected neurons, making the model more robust for molecular analysis. As such, these models are valuable for systematically dissecting the molecular details of latency establishment and maintenance, as well as the reactivation processes. In addition, a variety of ganglia types can be harvested and compared more easily than in vivo, which would require different infection sites. Comparing the efficiency of HSV latency in immature versus adult ganglia or sympathetic versus sensory ganglia, for example, may provide insight into specific neuronal molecular requirements for latency establishment, maintenance, or reactivation.

Nonetheless, rodent neurobiology is different than human neurobiology. The functional neuronal composition within anatomically distinct ganglia, for example, differs between species [83–85]. Therefore, specific molecular characteristics identified as important in rodent infection will need to be validated in human infections. One human autopsy study of TG was unable to identify a positive correlation of HSV-1 LAT expression in subtypes of nociceptive neurons [86], contradicting the notion (derived using animal models) of a viral preference for a specific subtype in latency establishment [80]. In addition, species differences exist in critical host molecules known to associate with viral proteins, with one example being Oct-1 [87]. As a result of these subtle differences in protein structure, VP16 has a lower affinity for rodent Oct-1 than for human Oct-1 [88]. As a component of the VP16-induced complex, Oct-1 is critical for driving IE gene expression, but this species-specific difference in protein affinity might confound findings involving viral molecular mechanisms and/or infection kinetics in rodents.

### 3.3. Human Neuronal Culture Models

Because access to primary human neuronal tissue is limited for ethical reasons, human neuron-like cell lines are an option to consider. Human neuroblastoma cell lines, such as SH-SY5Y cells, have been
explored as infection models for HSV infection. SH-SY5Y cells were subcloned from a cell line isolated from a bone marrow biopsy of a child with neuroblastoma, and are therefore believed to be of neural crest in origin. In culture, proliferating SH-SY5Y cells can be differentiated from epithelial-like cells into a homogenous population of cells with a branched-neuronal phenotype [89,90]. Differentiated SH-SY5Y cells have a higher efficiency of HSV-1 uptake compared to undifferentiated (proliferating) SH-SY5Y cells [91]. Typically SH-SY5Y cells have been used in lytic infection studies or herpesviral vector studies [91–93]; the prospect that SH-SY5Y cells might be useful as a human neuronal HSV latency model has not yet been fulfilled [94]. Recently, one group demonstrated “dormant” HSV-2 infection in undifferentiated SH-SY5Y by using acyclovir [95], but as undifferentiated cells, SH-SY5Y lack a neuronal-like phenotype and a non-productive infection was not experimentally confirmed.

In a similar manner, a human neuronally-committed teratocarcinoma cell line (NTera 2/D1, also known as NT2) can be induced by retinoic acid to differentiate into a neuronal-like phenotype designated hNT. Low-multiplicity infection by HSV-1 was impaired in such cells, and infection by ICP0-deficient viral strains resulted in a quiescent infection exhibiting some features of latency [96,97]. Given that replication-incompetent HSV vectors could persist for some time following infection of NT2 cells [97], they have been used for the further development of HSV-based viral vectors. However, little has been learned about the mechanisms of latency and reactivation in that setting.

Varicella zoster virus (VZV) is another human alphaherpesvirus that employs infection strategies similar to those of herpes simplex viruses. Without access to a neuronal cell line of human origin, the VZV field has taken advantage of the advancements in stem cell technology. Recently, a few infection models have been described based on human neurons differentiated from induced pluripotent stem cells (iPSCs) [98,99], neuronal stem cells [100], and embryonic stem cells [101,102]. Infection models using neurons from differentiated pluripotent cells are still in early stages, and as such major advances in HSV latency and reactivation specifically have not yet been made. In one study, approximately 80% of the cells derived after the differentiation of iPSCs were neuron-specific, but only 15% of the total cell population co-expressed sensory neuron markers [98]; using this model, undifferentiated iPSCs, neural precursor cells, and sensory neurons all supported lytic HSV-1 infection.

The process of neuronal differentiation results in a heterogeneous cell population wherein establishing latency may be challenging if permissive cells contribute to background virus production. For this reason, Gilden and colleagues began using iCells (Cellular Dynamics International), which are a mixture of post-mitotic neural subtypes derived from human iPSCs, in order to have a purer neuronal population in which to establish a latent, non-productive VZV infection [99]. To date, an HSV model has not been demonstrated in this relatively pure iPSC-derived cell line, but considering that iPSC-derived neurons are permissive to HSV-1 [98,103,104] infection, iCells may provide a promising human neuronal model in which to study HSV latency and reactivation.

An alternative approach to acquire human neurons in culture arises from cell lines established from neuronal tissue. For example, the HD10.6 cell line was derived from human DRG and proliferates via a tetracycline-regulated v-myc oncogene [105]. In the presence of doxycycline, cellular proliferation is suppressed and cells mature to exhibit a sensory neuron-associated phenotype (SNAP cells) [105,106]. These cells were immortalized using the same technique as the Lund human mesencephalic (LUHMES) cell line, which was isolated from human mesencephalon and is widely used in neurodegenerative disease studies [107,108]. HD10.6 is the first available human cell line derived specifically from sensory neurons. The cell line can be rapidly expanded and eliminates the requirement for animal usage.

We obtained HD10.6 cells in order to develop a human in vitro latency model in which to study HSV reactivation. Following the precedent of models using dissociated rodent ganglia [75], a single treatment of acyclovir enabled a non-productive, quiescent infection in a small subpopulation of matured HD10.6 cells (SNAP cells) at relatively low viral genome copy numbers per cell [106]. HSV-1 maintained the capacity to reactivate in this model, but NGF deprivation induced only a modestly increased probability of reactivation relative to spontaneous reactivation [106]. SNAP cells therefore provide the opportunity to determine whether the neutrophin-signaling network responsible for
maintaining latency in rodent ganglia is recapitulated in human neurons. In addition, the mechanism of LAT in HSV latency has never been studied directly in human sensory neurons and, at present, both LAT and lytic RNAs were repressed in this model. SNAP cells can be matured and infected in compartmented chambers and, like dissociated rodent ganglia [109,110], support axonal-only quiescent infections (unpublished data).

Human neuronal cell lines such as iCells or HD10.6 cells offer exciting platforms for studying the relevant molecular mechanisms of HSV latency in the natural host cell type. However, one caveat to consider is that, compared to in vivo rodent models, natural latent infection in human TG results in fewer neurons infected with HSV at lower genome copy numbers per cell [111]. Moreover, even in the face of external stressors, reactivation occurs infrequently in humans. Therefore, human-neuronal cell culture models may not prove to be as robust as rodent models and more advanced molecular techniques may be required.

4. Concluding Remarks and Future Directions

Advances in neuronal culturing techniques and the availability of high quality neuronal supplements have made it more feasible to study HSV latency and reactivation in dissociated ganglia from rodents. Technical approaches to culturing neurons, for example in fluidic chambers, have allowed sophisticated experimental designs in which viral and host mechanisms can be dissected based on spatial parameters more closely resembling natural infection. We have highlighted a variety of in vitro cell culture models that have been used to dissect critical viral and host mechanisms involved in the HSV latency cycle.

Studying latency mechanisms in neurons is ideal, but harvesting animal tissues is costly and tedious. Moreover, the field is aware of the caveats of using non-human models for human viral infections. Until recently, however, culturing human neurons for latent infection was not possible. Differentiation techniques have been fine-tuned such that relatively pure populations of neurons can be derived from human iPSCs or from commercial sources (iCells). An HSV latency model has yet to be demonstrated in iPSC-derived neurons and, although human, iPSC-derived neurons are not sensory-neuron specific. The HD10.6 cell line was derived from human dorsal root ganglia, and therefore more closely resembles sensory neurons.

It is intriguing to consider how latency mechanisms defined in the various cell culture models derived from different species will compare. Using these systems as complementary models to each other, various aspects of the molecular mechanisms of latency can be carefully dissected. Ultimately, the simplicity, reproducibility, and cost-effectiveness of these in vitro models will shed light on possible novel drug targets. Of course, with the simplification of cell culture comes the loss of critical contributing factors from the immunological or supporting environment in which a latently infected cell resides. The cancer field has demonstrated that contributions from surrounding non-tumor stroma and inflammatory cells (the microenvironment) can play significant roles in tumor progression, metastatic potential, and response to treatment. We predict that co-culturing of cells and organoid techniques will emerge as feasible tools for the analysis of HSV latency and will more accurately depict the physiology of latency while maintaining the benefits of an in vitro system.

Acknowledgments: The authors thank Van Andel Institute Graduate School and Van Andel Research Institute for financial and logistic support. The HSV latency field is robust and the literature is extensive; the authors apologize to those colleagues whose findings could not be cited directly.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Looker, K.J.; Magaret, A.S.; May, M.T.; Turner, K.M.E.; Vickerman, P.; Gottlieb, S.L.; Newman, L.M. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. *PLoS ONE* **2015**, *10*. [CrossRef] [PubMed]
2. Looker, K.J.; Magaret, A.S.; Turner, K.M.; Vickerman, P.; Gottlieb, S.L.; Newman, L.M. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. *PLoS ONE* 2015, 10, e114989. [CrossRef] [PubMed]

3. Mertz, G.J.; Benedetti, J.; Ashley, R.; Selke, S.A.; Corey, L. Risk factors for the sexual transmission of genital herpes. *Ann. Intern. Med.* 1992, 116, 197–202. [CrossRef] [PubMed]

4. Xu, F.; Lee, F.K.; Morrow, R.A.; Sternberg, M.R.; Ellsworth, M.G.; Wolff, P.A.; Deal, C.D.; Heineman, T.C.; Dubin, G.; et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. *Clin. Infect. Dis.* 2015, 56, 344–351. [CrossRef] [PubMed]

5. Xu, F.; Lee, F.K.; Morrow, R.A.; Sternberg, M.R.; Luther, K.E.; Dubin, G.; et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. *Clin. Infect. Dis.* 2015, 56, 344–351. [CrossRef] [PubMed]

6. Gupta, R.; Warren, T.; Wald, A. Genital herpes. *Lancet* 2007, 370, 2127–2137. [CrossRef]

7. Sanders, J.E.; Garcia, S.E. Pediatric herpes simplex virus infections: An evidence-based approach to treatment. *Pediatr. Emerg. Med. Pract.* 2014, 11, 1–19. [PubMed]

8. Burcea, M.; Gheorghe, A.; Pop, M. Incidence of herpes simplex virus keratitis in hiv/aids patients compared with the general population. *J. Med. Life.* 2015, 8, 62–63. [PubMed]

9. Tsatsos, M.; MacGregor, C.; Athanasiadis, I.; Moschos, M.M.; Hossain, P.; Anderson, D. Herpes simplex virus keratitis: An update of the pathogenesis and current treatment with oral and topical antiviral agents. *Clin. Exp. Ophthalmol.* 2016, 44, 824–837. [CrossRef] [PubMed]

10. Steiner, I.; Kennedy, P.G.; Pachner, A.R. The neurotropic herpes viruses: Herpes simplex and varicella-zoster. *Lancet Neurol.* 2007, 6, 1015–1028. [CrossRef] [PubMed]

11. Jaques, D.A.; Bagetakou, S.; L’Huillier, A.G.; Bartoli, A.; Vargas, M.I.; Fluss, J.; Kaiser, L. Herpes simplex encephalitis as a complication of neurosurgical procedures: Report of 3 cases and review of the literature. *Virology.* 2016, 513, 83. [CrossRef] [PubMed]

12. Kukhanova, M.K.; Korovina, A.N.; Kochetkov, S.N. Human herpes simplex virus: Life cycle and development of inhibitors. *Biochemistry (Mosc)* 2014, 79, 1635–1652. [CrossRef] [PubMed]

13. Ellion, G.B.; Furman, P.A.; Fyfe, J.A.; de Miranda, P.; Beauchamp, L.; Schaeffer, H.J. Selectivity of action of an antiviral agent, 9-(2-hydroxyethoxymethyl) guanine. *Proc. Natl. Acad. Sci. USA* 1977, 74, 5716–5720. [CrossRef] [PubMed]

14. Koelle, D.M.; Wald, A. Herpes simplex virus: The importance of asymptomatic shedding. *J. Antimicrob. Chemother* 2000, 45 Suppl T3, 1–8. [CrossRef] [PubMed]

15. Morfin, F.; Thouvenot, D. Herpes simplex virus resistance to antiviral drugs. *J. Clin. Virol.* 2003, 26, 29–37. [CrossRef]

16. Grey, F.; Sowa, M.; Collins, P.; Fenton, R.J.; Harris, W.; Snowden, W.; Elstathiu, S.; Darby, G. Characterization of a neurovirulent aciclovir-resistant variant of herpes simplex virus. *J. Gen. Virol.* 2003, 84, 1403–1410. [CrossRef] [PubMed]

17. Stranska, R.; Schuurman, R.; Nienhuys, E.; Goedegebuure, I.W.; Polman, M.; Weel, J.F.; Wertheim-Van Dillen, P.M.; Berkhout, R.J.; van Loon, A.M. Survey of acyclovir-resistant herpes simplex virus in the netherlands: Prevalence and characterization. *J. Clin. Virol.* 2005, 32, 7–18. [CrossRef] [PubMed]
22. Frobert, E.; Burrel, S.; Ducastelle-Lepretre, S.; Billaud, G.; Ader, F.; Casalegno, J.S.; Nave, V.; Boutolleau, D.; Michallet, M.; Lina, B.; et al. Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in france. *Antiviral. Res.* 2014, 111, 36–41. [CrossRef] [PubMed]

23. Van Velzen, M.; van de Vijver, D.A.; van Loenen, E.B.; Osterhaus, A.D.; Remeijer, L.; Verjans, G.M. Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. *J. Infect. Dis.* 2013, 208, 1359–1365. [PubMed]

24. Sawtell, N.M.; Poon, D.K.; Tansky, C.S.; Thompson, R.L. The latent herpes simplex virus type 1 genome transcriptional activation in the nervous system in vivo. *Methods Mol. Biol.* 2005, 292, 57–72. [PubMed]

25. Sawtell, N.M.; Poon, D.K.; Tansky, C.S.; Thompson, R.L. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. *J. Virol.* 1998, 72, 5343–5350. [PubMed]

26. Bloom, D.C. Alpha-herpesvirus latency: A dynamic state of transcription and reactivation. *Adv. Virus Res.* 2016, 94, 53–80. [PubMed]

27. Gerster, T.; Roeder, R.G. A herpesvirus trans-activating protein interacts with transcription factor otf-1 and other cellular proteins. *Proc. Natl. Acad. Sci. USA* 1988, 85, 6347–6351. [CrossRef] [PubMed]

28. Christie, T.M.; Sharp, P.A. Interactions of the Oct-1 pou subdomains with specific DNA sequences and with the hsp alpha-trans-activator protein. *Genes Dev.* 1990, 4, 2383–2396. [CrossRef] [PubMed]

29. Hagmann, M.; Georgiev, O.; Schaffner, W.; Douville, P. Transcription factors interacting with herpes simplex virus alpha gene promoters in sensory neurons. *Nucleic. Acids Res.* 1995, 23, 4978–4985. [CrossRef] [PubMed]

30. Campbell, M.E.; Palfreyman, J.W.; Preston, C.M. Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. *J. Mol. Biol.* 1984, 180, 1–19. [PubMed]

31. Dalrymple, M.A.; McGeoch, D.J.; Davison, A.J.; Preston, C.M. DNA sequence of the herpes simplex virus type 1 gene whose product is responsible for transcriptional activation of immediate early promoters. *Nucleic. Acids Res.* 1985, 13, 7865–7879. [CrossRef] [PubMed]

32. Wysocka, J.; Herr, W. The herpes simplex virus vp16-induced complex: The makings of a regulatory switch. *Trends Biochem. Sci.* 2003, 28, 294–304. [CrossRef]

33. Honess, R.W.; Roizman, B. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. *J. Virol.* 1974, 14, 8–19. [PubMed]

34. Scherer, J.; Yaffe, Z.A.; Vershinin, M.; Enquist, L.W. Dual-color herpesvirus capsids discriminate inoculum from progeny and reveal axonal transport dynamics. *J. Virol.* 2016. [CrossRef] [PubMed]

35. Hafezi, W.; Lorentzen, E.U.; Eing, B.R.; Muller, M.; King, N.J.; Klupp, B.; Mettenleiter, T.C.; Kuhn, J.E. Entry of herpes simplex virus type 1 (HSV-1) into the distal axons of trigeminal neurons favors the onset of nonproductive, silent infection. *PLoS Pathog.* 2012, 8, e1002679. [CrossRef] [PubMed]

36. Luxton, G.W.; Haverlock, S.; Coller, K.E.; Antinone, S.E.; Pincetic, A.; Smith, G.A. Targeting of herpesvirus capsid transport in axons is coupled to association with specific sets of tegument proteins. *Proc. Natl. Acad. Sci. USA* 2005, 102, 5832–5837. [CrossRef] [PubMed]

37. Lee, J.S.; Raja, P.; Knipe, D.M. Herpesviral icp0 protein promotes two waves of heterochromatin removal on an early viral promoter during lytic infection. *MBio* 2016, 7, e02007–e02015. [CrossRef] [PubMed]

38. Conn, K.L.; Schang, L.M. Chromatin dynamics during lytic infection with herpes simplex virus 1. *Virology* 2013, 5, 1758–1786. [CrossRef] [PubMed]

39. Denslowe, S.L.; Fraser, N.W. During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. *J. Virol.* 1989, 63, 943–947. [PubMed]

40. Bloom, D.C.; Giordani, N.V.; Kwiatkowski, D.L. Epigenetic regulation of latent HSV-1 gene expression. *Biochim. Biophys Acta* 2010, 1799, 246–256. [CrossRef] [PubMed]

41. Kim, J.Y.; Mandarino, A.; Chao, M.V.; Mohr, I.; Wilson, A.C. Transient reversal of episome silencing precedes vp16-dependent transcription during reactivation of latent HSV-1 in neurons. *PLoS Pathog.* 2012, 8, e1002540. [CrossRef] [PubMed]

42. Cliffe, A.R.; Garber, D.A.; Knipe, D.M. Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters. *J. Virol.* 2009, 83, 8182–8190. [CrossRef] [PubMed]

43. Wagner, E.K.; Bloom, D.C. Experimental investigation of herpes simplex virus latency. *Clin. Microbiol. Rev.* 1997, 10, 419–443. [PubMed]
44. Nicholl, M.P.; Hann, W.; Shivkumar, M.; Harman, L.E.; Connor, V.; Coleman, H.M.; Prenen, J.; Efstathiou, S. The HSV-1 latency-associated transcript functions to repress latent phase lytic gene expression and suppress virus reactivation from latently infected neurons. PLoS Pathog. 2016, 12, e1005539. [CrossRef] [PubMed]

45. Sawtelle, N.M.; Thompson, R.L. Herpes simplex virus and the lexicon of latency and reactivation: A call for defining terms and building an integrated collective framework. F1000Res 2016, 5. [CrossRef] [PubMed]

46. Preston, C.M.; Efstathiou, S. Mammalian basis of hsv latency and reactivation. In Human herpesviruses: Biology, therapy, and immunophrophylaxis; Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K., Eds.; Cambridge University Press: Cambridge, UK, 2007.

47. Cohrs, R.J.; Badani, H.; Bos, N.; Scianca, C.; Hoskins, I.; Baird, N.L.; Gilden, D. Alpha-herpesvirus DNA replication in dissociated human trigeminal ganglia. J. Neurovirol. 2016, 22, 688–694. [CrossRef] [PubMed]

48. Steiner, I.; Benninger, F. Update on herpesvirus infections of the nervous system. Curr. Neural. Neurosci. Rep. 2013, 13, 414. [CrossRef] [PubMed]

49. Furuta, Y.; Takasu, T.; Fukuda, S.; Inuyama, Y.; Sato, K.C.; Nagashima, K. Latent herpes simplex virus type 1 in human vestibular ganglia. Acta Otolaryngol. Suppl. 1993, 503, 85–89. [CrossRef] [PubMed]

50. Warren, K.G.; Brown, S.M.; Wroblewska, Z.; Gilden, D.; Koprowski, H.; Subak-Sharpe, J. Isolation of latent herpes simplex virus from the superior cervical and vagus ganglia of human beings. N. Engl. J. Med. 1978, 298, 1068–1069. [CrossRef] [PubMed]

51. Lee, S.; Ives, A.M.; Bertke, A.S. Herpes simplex virus 1 reactivates from autonomic ciliary ganglia independently from sensory trigeminal ganglia to cause recurrent ocular disease. J. Virol. 2015, 89, 8383–8391. [CrossRef] [PubMed]

52. Ohashi, M.; Bertke, A.S.; Patel, A.; Krause, P.R. Spread of herpes simplex virus to the spinal cord is independent of spread to dorsal root ganglia. J. Virol. 2011, 85, 3030–3032. [CrossRef] [PubMed]

53. Higaki, S.; Fukuda, M.; Shimomura, Y. Virological and molecular biological evidence supporting herpes simplex virus type 1 as the cause of recurrent keratitis. J. Gen. Virol. 2008, 89, 804–814. [CrossRef] [PubMed]

54. Scheck, A.C.; Wigdahl, B.; De Clercq, E.; Rapp, F. Prolonged herpes simplex virus latency in vitro after treatment of infected cells with acyclovir and human leukocyte interferon. Antimicrob. Agents Chemother. 1986, 29, 589–593. [CrossRef] [PubMed]

55. Shiraki, K.; Rapp, F. Establishment of herpes simplex virus latency in vitro with cycloheximide. J. Gen. Virol. 1986, 67 Pt 11, 2497–2500. [CrossRef] [PubMed]

56. Russell, J.; Preston, C.M. An in vitro latency system for herpes simplex virus type 2. J. Gen. Virol. 1986, 67 Pt 2, 397–403. [CrossRef] [PubMed]

57. Harris, R.A.; Preston, C.M. Establishment of latency in vitro by the herpes simplex virus type 1 mutant in1814. J. Gen. Virol. 1991, 72 Pt 4, 907–913. [CrossRef] [PubMed]

58. McManus, R.; Walsh, D. Efficient quiescent infection of normal human diploid fibroblasts with wild-type herpes simplex virus type 1. J. Virol. 2008, 82, 10218–10230. [CrossRef] [PubMed]

59. Greene, L.A.; Tischler, A.S. Establishment of a quiescent herpes simplex virus infection in normal human diploid fibroblasts. J. Gen. Virol. 1977, 39, 573–583. [CrossRef] [PubMed]

60. Warren, K.G.; Brown, S.M.; Wroblewska, Z.; Gilden, D.; Koprowski, H.; Subak-Sharpe, J. Isolation of latent herpes simplex virus from the superior cervical and vagus ganglia of human beings. N. Engl. J. Med. 1978, 298, 1068–1069. [CrossRef] [PubMed]

61. Steiner, I.; Bendinger, F. Update on herpes virus infections of the nervous system. Curr. Neural. Neurosci. Rep. 2013, 13, 414. [CrossRef] [PubMed]

62. Danaher, R.J.; Cook, R.K.; Wang, C.; Triezenberg, S.J.; Jacob, R.J.; Miller, C.S. C-terminal trans-activation sub-region of vp16 is uniquely required for forskolin-induced herpes simplex virus type 1 reactivation from quiescently infected-pc12 cells but not for replication in neuronal-differentiated-pc12 cells. J. Neurovirol. 2013, 19, 32–41. [CrossRef] [PubMed]
65. Jurak, I.; Hackenberg, M.; Kim, J.Y.; Pesola, J.M.; Everett, R.D.; Preston, C.M.; Wilson, A.C.; Coen, D.M. Expression of herpes simplex virus 1 micrornas in cell culture models of quiescent and latent infection. *J. Virol.* 2014, 88, 2337–2339. [CrossRef] [PubMed]

66. Lakin, N.D.; Palmer, R.; Lillycrop, K.A.; Howard, M.K.; Burke, L.C.; Thomas, N.S.; Latchman, D.S. Down regulation of the octamer binding protein Oct-1 during growth arrest and differentiation of a neuronal cell line. *Brain Res. Mol. Brain Res.* 1995, 28, 47–54. [CrossRef]

67. Turner, E.E.; Fedtsova, N.; Rosenfeld, M.G. Pou-domain factor expression in the trigeminal ganglion and implications for herpes virus regulation. *Neuroreport* 1996, 7, 2829–2832. [CrossRef] [PubMed]

68. Zargar, Z.; Tyagi, S. Role of host cell factor-1 in cell cycle regulation. *J. Biol. Chem.* 2002, 277, 44292–44299. [CrossRef] [PubMed]

69. Mahajan, S.S.; Little, M.M.; Vazquez, R.; Wilson, A.C. Interaction of HCF-1 with a cellular nuclear export factor. *J. Biol. Chem.* 2002, 277, 44292–44299. [CrossRef] [PubMed]

70. Kolb, G.; Kristie, T.M. Association of the cellular coactivator HCF-1 with the golgi apparatus in sensory neurons. *J. Virol.* 2008, 82, 9555–9563. [CrossRef] [PubMed]

71. Kobayashi, M.; Wang, V.E.; Tantin, D.; Sharp, P.A.; Kristie, T.M. Herpes simplex virus infections are arrested in Oct-1-deficient cells. *Proc. Natl. Acad. Sci. USA* 2004, 101, 1473–1478. [CrossRef] [PubMed]

72. Wilcox, C.L.; Johnson, E.M., Jr. Nerve growth factor deprivation results in the reactivation of latent herpes simplex virus in vitro. *J. Virol.* 1987, 61, 2311–2315. [PubMed]

73. Wilcox, C.L.; Johnson, E.M., Jr. Characterization of nerve growth factor-dependent herpes simplex virus latency in neurons in vitro. *J. Virol.* 1988, 62, 393–399. [PubMed]

74. Arthur, J.L.; Scarppini, C.G.; Connor, V.; Lachmann, R.H.; Tolkovsky, A.M.; Efstathiou, S. Herpes simplex virus type 1 promoter activity during latency establishment, maintenance, and reactivation in primary dorsal root neurons in vitro. *J. Virol.* 2001, 75, 3885–3895. [CrossRef] [PubMed]

75. Jurak, I.; Hackenberg, M.; Kim, J.Y.; Pesola, J.M.; Everett, R.D.; Preston, C.M.; Wilson, A.C.; Coen, D.M. Neuronal stress pathway mediating a histone methyl/phospho switch is required for herpes virus regulation. *Neuroreport* 2015, 26, 44292–44299. [CrossRef] [PubMed]

76. Bertke, A.S.; Ma, A.; Margolis, M.S.; Margolis, T.P. Different mechanisms regulate productive herpes simplex virus 1 (HSV-1) and HSV-2 infections in adult trigeminal neurons. *J. Virol.* 2013, 87, 6512–6516. [CrossRef] [PubMed]

77. Bertke, A.S.; Swanson, S.M.; Chen, J.; Imai, Y.; Kinchington, P.R.; Margolis, T.P. A5-positive primary sensory neurons are nonpermissive for productive infection with herpes simplex virus 1 in vitro. *J. Virol.* 2011, 85, 6669–6677. [CrossRef] [PubMed]

78. Margolis, T.P.; Imai, Y.; Yang, L.; Vallas, V.; Krause, P.R. Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: Role of latency-associated transcripts. *J. Virol.* 2007, 81, 1872–1878. [CrossRef] [PubMed]

79. Josephson, A.; Widenfalk, J.; Trifunovski, A.; Widmer, H.R.; Olson, L.; Spenger, C. Gdnf and ngf family members and receptors in human fetus and adult spinal cord and dorsal root ganglia. *J. Comp. Neurol.* 2001, 440, 204–217. [CrossRef] [PubMed]

80. Lawson, S.N.; Waddell, P.J. Soma neurofilament immunoreactivity is related to cell size and fibre conduction velocity in rat primary sensory neurons. *J. Physiol.* 1991, 435, 41–63. [CrossRef] [PubMed]

81. Margolis, T.P.; Imai, Y.; Yang, L.; Vallas, V.; Krause, P.R. Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: Role of latency-associated transcripts. *J. Virol.* 2007, 81, 1872–1878. [CrossRef] [PubMed]

82. Cliffe, A.R.; Arbuckle, J.H.; Vogel, J.L.; Geden, M.J.; Rothbart, S.B.; Cusack, C.L.; Strahl, B.D.; Kristie, T.M.; Deshmukh, M. Neuronal stress pathway mediating a histone methyl/phospho switch is required for herpes simplex virus reactivation. *Cell Host Microbe* 2015, 18, 649–658. [CrossRef] [PubMed]

83. Josephson, A.; Widenfalk, J.; Trifunovski, A.; Widmer, H.R.; Olson, L.; Spenger, C. Gdnf and ngf family members and receptors in human fetus and adult spinal cord and dorsal root ganglia. *J. Comp. Neurol.* 2001, 440, 204–217. [CrossRef] [PubMed]

84. Lawson, S.N.; Waddell, P.J. Soma neurofilament immunoreactivity is related to cell size and fibre conduction velocity in rat primary sensory neurons. *J. Physiol.* 1991, 435, 41–63. [CrossRef] [PubMed]

85. Lawson, S.N. Morphological and biochemical cell types of sensory neurons. In *Sensory Neurons. Diversity, Development, and Plasticity*; Oxford University Press: New York, NY, USA, 1992; pp. 27–59.
86. Flowerdew, S.E.; Wick, D.; Himmelstein, S.; Horn, A.K.; Sinicina, I.; Strupp, M.; Brandt, T.; Theil, D.; Hufner, K. Characterization of neuronal populations in the human trigeminal ganglion and their association with latent herpes simplex virus-1 infection. PlOSS ONE 2013, 8, e83603. [CrossRef] [PubMed]

87. Suzuki, N.; Peter, W.; Ciesiolka, T.; Gruss, P.; Scholer, H.R. Mouse Oct-1 contains a composite homeodomain of human Oct-1 and Oct-2. Nucleic. Acids. Res. 1993, 21, 245–252. [CrossRef] [PubMed]

88. Cleary, M.A.; Stern, S.; Tanaka, M.; Herr, W. Differential positive control by Oct-1 and Oct-2: Activation of a transcriptionally silent motif through Oct-1 and vp16 corecruitment. Genes Dev. 1993, 7, 72–83. [CrossRef] [PubMed]

89. Encinas, M.; Iglesias, M.; Liu, Y.; Wang, H.; Muhaisen, A.; Cena, V.; Gallego, C.; Comella, J.X. Sequential treatment of sh-sy5y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J. Neurochem. 2000, 75, 991–1003. [CrossRef] [PubMed]

90. Constantinescu, R.; Constantinescu, A.T.; Reichmann, H.; Janetzky, B. Neuronal differentiation and long-term culture of the human neuroblastoma line sh-sy5y. J. Neural. Transm. Suppl. 2007, 72, 17–28.

91. Gimenez-Cassina, A.; Lim, F.; Diaz-Nido, J. Differentiation of a human neuroblastoma into neuron-like cells increases their susceptibility to transduction by herpesviral vectors. J. Neurosci. Res. 2006, 84, 755–767. [CrossRef] [PubMed]

92. De Chiara, G.; Marcocci, M.E.; Civitelli, L.; Argnani, R.; Piacentini, R.; Ripoli, C.; Manservigi, R.; Grassi, C.; Garaci, E.; Palamara, A.T. App processing induced by herpes simplex virus type 1 (HSV-1) yields several app fragments in human and rat neuronal cells. PlOSS ONE 2010, 5, e13989. [CrossRef] [PubMed]

93. Christensen, J.; Steain, M.; Slobedman, B.; Abendroth, A. Differentiated neuroblastoma cells provide a highly efficient model for studies of productive varicella-zoster virus infection of neuronal cells. J. Virol. 2011, 85, 8436–8442. [CrossRef] [PubMed]

94. Shipley, M.M.; Mangold, C.A.; Szpara, M.L. Differentiation of the sh-sy5y human neuroblastoma cell line. J. Vis. Exp. 2016, 53193. [CrossRef] [PubMed]

95. Sun, Z.; Yang, H.; Shi, Y.; Wei, M.; Xian, J.; Hu, W. Establishment of a cell model system of herpes simplex virus type ii latent infection and reactivation in sh-sy5y cells. Wei Sheng Wu Xue Bao 2010, 50, 98–106. [PubMed]

96. Hsu, W.L.; Everett, R.D. Human neuron-committed teratocarcinoma nt2 cell line has abnormal nd10 structures and is poorly infected by herpes simplex virus type 1. J. Virol. 2001, 75, 3819–3831. [CrossRef] [PubMed]

97. Weir, J.P. Infection of human nt2 cells and differentiated nt-neurons with herpes simplex virus and replication-incompetent herpes simplex virus vectors. J. Neurovirol. 2001, 7, 43–51. [CrossRef] [PubMed]

98. Yu, X.; Seitz, S.; Pointon, T.; Bowlin, J.L.; Cohrs, R.J.; Jonjic, S.; Haas, J.; Wellish, M.; Gilden, D. Varicella-zoster virus infection of highly pure terminally differentiated human neurons. J. Neurovirol. 2013, 19, 75–81. [CrossRef] [PubMed]

99. Pugazhenthi, S.; Nair, S.; Velmurugan, K.; Liang, Q.; Mahalingam, R.; Cohrs, R.J.; Nagel, M.A.; Gilden, D. Varicella-zoster virus infection of differentiated human neural stem cells. J. Virol. 2011, 85, 6678–6686. [CrossRef] [PubMed]

100. Dukhovny, A.; Sloutskin, A.; Markus, A.; Yee, M.B.; Kinchington, P.R.; Goldstein, R.S. Varicella-zoster virus infects human embryonic stem cell-derived neurons and neurospheres but not pluripotent embryonic stem cells or early progenitors. J. Virol. 2012, 86, 3211–3218. [CrossRef] [PubMed]

101. Markus, A.; Lenthall-Loinger, I.; Yang, I.H.; Kinchington, P.R.; Goldstein, R.S. An in vitro model of latency and reactivation of varicella zoster virus in human stem cell-derived neurons. PLoS Pathog. 2015, 11, e1004885. [CrossRef] [PubMed]

102. D’Aiuto, L.; Williamson, K.; Dimitrion, P.; McNulty, J.; Brown, C.E.; Dokuburra, C.B.; Nielsen, A.J.; Lin, W.J.; Piazza, P.; Schurdak, M.E.; et al. Comparison of three cell-based drug screening platforms for HSV-1 infection. Antiviral. Res. 2017, 142, 136–140. [CrossRef] [PubMed]
104. D’Aiuto, L.; Prasad, K.M.; Upton, C.H.; Viggiano, L.; Milosevic, J.; Raimondi, G.; McClain, L.; Chowdari, K.; Tischfield, J.; Sheldon, M.; et al. Persistent infection by HSV-1 is associated with changes in functional architecture of ipsc-derived neurons and brain activation patterns underlying working memory performance. *Schizophr. Bull.* 2015, 41, 123–132. [CrossRef] [PubMed]

105. Raymon, H.K.; Thode, S.; Zhou, J.; Friedman, G.C.; Pardinas, J.R.; Barrere, C.; Johnson, R.M.; Sah, D.W. Immortalized human dorsal root ganglion cells differentiate into neurons with nociceptive properties. *J. Neurosci.* 1999, 19, 5420–5428. [PubMed]

106. Thellman, N.M.; Botting, C.; Madaj, Z.; Triezenberg, S.J. An immortalized human dorsal root ganglia cell line provides a novel context to study herpes simplex virus type-1 latency and reactivation. *J. Virol.* 2017, 91. [CrossRef] [PubMed]

107. Lotharius, J.; Barg, S.; Wiekop, P.; Lundberg, C.; Raymon, H.K.; Brundin, P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. *J. Biol. Chem.* 2002, 277, 38884–38894. [CrossRef] [PubMed]

108. Lotharius, J.; Falsig, J.; van Beek, J.; Payne, S.; Dringen, R.; Brundin, P.; Leist, M. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. *J. Neurosci.* 2005, 25, 6329–6342. [CrossRef] [PubMed]

109. Campenot, R.B. Local control of neurite development by nerve growth factor. *Proc. Natl. Acad. Sci. USA* 1977, 74, 4516–4519. [CrossRef] [PubMed]

110. Curanovic, D.; Ch’ng, T.H.; Szpara, M.; Enquist, L. Compartmented neuron cultures for directional infection by alpha herpesviruses. *Curr Protoc Cell Biol.* 2009. [CrossRef]

111. Cai, G.Y.; Pizer, L.I.; Levin, M.J. Fractionation of neurons and satellite cells from human sensory ganglia in order to study herpesvirus latency. *J. Virol. Methods* 2002, 104, 21–32. [CrossRef]